Discussing highlights from ESMO in breast cancer: Pfizer's CDK4-selective inhibitor PF-07220060, Arvinas/Pfizer Vepdegestrant/palbociclib combo & Olema's palazestrant/ribociclib combo

Executed on:Jun 10, 2024 9:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Cambridge

Clinical Senior Research Associate and Academic Consultant in Breast Cancer Therapeutics at the University of Cambridge.
Currently manages 30 patients with HR+/HER- breast cancer each month.
Focus on Early phase breast cancer clinical trials with expertise in first-in-human studies & drug combination trials, new small molecule & antibody therapeutics and the development of pharmacodynamic and predictive biomarkers.

Interview Goal

Discussing updates of interest at ESMO-BC

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.